Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

The Efficacy and Safety of Selinexor in Combination with Ruxolitinib in Ruxolitinib-Treated Myelofibrosis Patients: The Interim Analysis of a Prospective, Open-Label, Multicenter, Parallel-Cohort, Phase 2 Study

Minghui Duan, Lan Ma, Qiuling Wu, Hong Liang, Wei Wang, Lijun Mu, Hai Lin, Hebing Zhou, Hong-xia Shi, Jinghua Wang, Hongmei Jing

Blood (2024) 144 (Supplement 1): 1002.

https://doi.org/10.1182/blood-2024-201204

Published: 2024

Journal Articles

A Completely Oral Regimen Including Oral Etoposide As Cytoreductive Chemotherapy Combined with All Trans Retinoic Acid and Oral Arsenic for Induction Therapy in Patients with High-Risk APL：Comparable to Intravenous Cytoreductive Therapy

Feifei Tang, Wen-Bing Duan, Xiao-Hong Liu, Sheng-Ye Lu, Xiao-Su Zhao, Ya-Zhen Qin, Jin-Song Jia, Jing Wang, Li-Zhong Gong, Qian Jiang, Zhao Ting, Hong-Xia Shi, Ying-Jun Chang, Xiao-Jun Huang, Hao Jiang

Blood (2023) 142 (Supplement 1): 4288.

https://doi.org/10.1182/blood-2023-188657

Published: 2023

Journal Articles

Comparison of Safety and Efficacy between Venetoclax Combined with CAG (cytarabine, aclarubicin, G-CSF) Regimen and CAG Regimen Alone in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Wen-Jing Yu, Ying Wu, Qi Chen, Xiaolu Zhu, Xu-Ying Pei, Jin-Song Jia, Jing Wang, Xiao-Su Zhao, Ying-Jun Chang, Yue-Yun Lai, Hong-Xia Shi, Guo-Rui Ruan, Ya-Zhen Qin, Xiao-Hong Liu, Xiao Jun Huang, Hao Jiang

Blood (2023) 142 (Supplement 1): 1525.

https://doi.org/10.1182/blood-2023-184665

Published: 2023

Journal Articles

The Efficacy and Safety of Selinexor in Combination with Ruxolitinib in Ruxolitinib-Treated Myelofibrosis Patients： the Interim Analysis of a Prospective, Open-Label, Multicenter, Parallel-Cohort, Phase 2 Study

Minghui Duan, Lan Ma, Qiuling Wu, Hong Liang, Wei Wang, Shaoling Wu, Lijun Mu, Hai Lin, Hebing Zhou, Hong-Xia Shi, Jinghua Wang, Hongmei Jing

Blood (2023) 142 (Supplement 1): 4578.

https://doi.org/10.1182/blood-2023-188037

Published: 2023

Journal Articles

Tacrolimus Plus High-Dose Dexamethasone Versus High-Dose Dexamethasone Alone As First-Line Treatment for Adult Immune Thrombocytopenia: The Phase 2, Open Label, Randomized Trial (TARGET 020)

Blood (2021) 138 (Supplement 1): 13.

https://doi.org/10.1182/blood-2021-152111

Published: 2021

Journal Articles

A Clinical Study of 15 Acute Leukemia Patients with Plasmacytoid Dendritic Cells Expansion

Ya-Lan Zhou, Yan Wei, Xiaohong Liu, Jing Wang, Jinsong Jia, Hong-Xia Shi, Ying-Jun Chang, Xiao-Su Zhao, Yan-Rong Liu, Guo-Rui Ruan, Xiao-Jun Huang, Hao Jiang

Blood (2021) 138 (Supplement 1): 4468.

https://doi.org/10.1182/blood-2021-149623

Published: 2021

Journal Articles

Interferon May Help Control the Recurrence of Chronic Myeloid Leukemia after Discontinuation of Tyrosine Kinase Inhibitor

Jun Kong, MD, Xiao-Hong Liu, Ya-Zhen Qin, Hong-Xia Shi, Yue-Yun Lai, Xiao-Jun Huang, Hao Jiang

Blood (2018) 132 (Supplement 1): 4270.

https://doi.org/10.1182/blood-2018-99-119063

Published: 2018

Journal Articles

Interim Results of a Multi-Center Observational Study of Current Treatment Patterns for Patients with Severe Aplastic Anemia (SAA), Very Severe Aplastic Anemia (VSAA) and Transfusion-Dependent Non-Severe Aplastic Anemia (TD-NSAA) in China

Blood (2015) 126 (23): 4505.

https://doi.org/10.1182/blood.V126.23.4505.4505

Published: 2015

Journal Articles

Prevalence and Prognostic Significance of c-KIT Mutations in Core Binding Factor Acute Myeloid Leukemia: A Comprehensive Large-Scale Study from a Single Chinese Center

Ya-Zhen Qin, Honghu Zhu, Qian Jiang, Hao Jiang, Le-Ping Zhang, Jin-Lan Li, Ling-Di Li, Yan-Rong Liu, Yue-Yun Lai, Hong-Xia Shi, Bin Jiang, MD, Xiao-Jun Huang, MDPhD

Blood (2014) 124 (21): 1000.

https://doi.org/10.1182/blood.V124.21.1000.1000

Published: 2014

Journal Articles

Chronic Myelogenous Leukemia Patients with Highly Nilotinib-Resistant BCR-ABL Mutations Demonstrate Similar Efficacy to Dasatinib, but Have a Higher Likelihood of Developing New Mutations in the Event of Clinical Resistance

Qian Jiang, MD, Ya-Zhen Qin, MS, Yue-Yun Lai, MD, Bin Jiang, MD, Hao Jiang, Hong-Xia Shi, MD, Xiao-Jun Huang, MD

Blood (2012) 120 (21): 3755.

https://doi.org/10.1182/blood.V120.21.3755.3755

Published: 2012

Journal Articles

The PRAME and WT1 Transcripts Constitute a Good Molecular Marker Combination for Monitoring Minimal Residual Disease in Myelodysplastic Syndromes

Yazhen Qin, Honghu Zhu, PhD, Yan-rong Liu, MD, Ya-zhe Wang, Hong-Xia Shi, Yue-yun Lai, Lan-Ping Xu, MD, Daihong Liu, Xiaojun Huang

Blood (2012) 120 (21): 3853.

https://doi.org/10.1182/blood.V120.21.3853.3853

Published: 2012

Journal Articles

Imatinib Mesylate Is Superior to Allogeneic Hematopoietic Stem Cell Transplantation As the First-Line Therapy for Patients with Chronic Myeloid Leukemia in the Early Chronic Phase

Blood (2011) 118 (21): 162.

https://doi.org/10.1182/blood.V118.21.162.162

Published: 2011

Journal Articles

HLA Mismatched/Haploidentical Haematopoietic Stem Cell Transplantation for the Treatment of Chronic Myelogenous Leukemia.

Xiao Jun Huang, Lan-ping Xu, Kai-yan Liu, Dai-hong Liu, Huan Chen, Wei Han, Yu-hong Chen, Jing-zhi Wang, Yao Chen, Xiao-hui Zhang, Hong-xia Shi, Dao-pei Lu

Blood (2006) 108 (11): 3154.

https://doi.org/10.1182/blood.V108.11.3154.3154

Published: 2006

Journal Articles

Transplantation of HLA-Mismatched Stem Cell Transplantation without T Cell Depletion for the Treatment of Malignant Hematological Disease.

Xiao jun Huang, MD, PhD, Daihong Liu, MDPh.D, Kai Yan Liu, MDPh.D, Lan ping Xu, MD, Huan Chen, MD, Wei Han, MD, Yu Hong Chen, MD, Jing zhi Wang, MD, Zhi yong Gao, MD, Yao Chen Zhang, MD, Qian Jiang, MD, Hong xia Shi, MD, Dao pei Lu, MD

Blood (2005) 106 (11): 2915.

https://doi.org/10.1182/blood.V106.11.2915.2915

Published: 2005

NARROW

The Efficacy and Safety of Selinexor in Combination with Ruxolitinib in Ruxolitinib-Treated Myelofibrosis Patients: The Interim Analysis of a Prospective, Open-Label, Multicenter, Parallel-Cohort, Phase 2 Study

A Completely Oral Regimen Including Oral Etoposide As Cytoreductive Chemotherapy Combined with All Trans Retinoic Acid and Oral Arsenic for Induction Therapy in Patients with High-Risk APL：Comparable to Intravenous Cytoreductive Therapy

Comparison of Safety and Efficacy between Venetoclax Combined with CAG (cytarabine, aclarubicin, G-CSF) Regimen and CAG Regimen Alone in Patients with Relapsed or Refractory Acute Myeloid Leukemia

The Efficacy and Safety of Selinexor in Combination with Ruxolitinib in Ruxolitinib-Treated Myelofibrosis Patients： the Interim Analysis of a Prospective, Open-Label, Multicenter, Parallel-Cohort, Phase 2 Study

Tacrolimus Plus High-Dose Dexamethasone Versus High-Dose Dexamethasone Alone As First-Line Treatment for Adult Immune Thrombocytopenia: The Phase 2, Open Label, Randomized Trial (TARGET 020)

A Clinical Study of 15 Acute Leukemia Patients with Plasmacytoid Dendritic Cells Expansion

Interferon May Help Control the Recurrence of Chronic Myeloid Leukemia after Discontinuation of Tyrosine Kinase Inhibitor

Interim Results of a Multi-Center Observational Study of Current Treatment Patterns for Patients with Severe Aplastic Anemia (SAA), Very Severe Aplastic Anemia (VSAA) and Transfusion-Dependent Non-Severe Aplastic Anemia (TD-NSAA) in China

Prevalence and Prognostic Significance of c-KIT Mutations in Core Binding Factor Acute Myeloid Leukemia: A Comprehensive Large-Scale Study from a Single Chinese Center

Chronic Myelogenous Leukemia Patients with Highly Nilotinib-Resistant BCR-ABL Mutations Demonstrate Similar Efficacy to Dasatinib, but Have a Higher Likelihood of Developing New Mutations in the Event of Clinical Resistance

The PRAME and WT1 Transcripts Constitute a Good Molecular Marker Combination for Monitoring Minimal Residual Disease in Myelodysplastic Syndromes

Imatinib Mesylate Is Superior to Allogeneic Hematopoietic Stem Cell Transplantation As the First-Line Therapy for Patients with Chronic Myeloid Leukemia in the Early Chronic Phase

HLA Mismatched/Haploidentical Haematopoietic Stem Cell Transplantation for the Treatment of Chronic Myelogenous Leukemia.

Transplantation of HLA-Mismatched Stem Cell Transplantation without T Cell Depletion for the Treatment of Malignant Hematological Disease.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only